Should Big Cryptocrime Sow Doubt in Crypto’s Safety?

 

The Feds just seized nearly $3.4 billion in stolen bitcoin from a cryptothief. This is clearly bad news for that thief, but it also begs the question: Is this a PR problem for the crypto industry? If you can steal billions in crypto assets, is the decentralized infrastructure really all that safe for companies to engage with? Should companies expect cryptocrime on their decentralized ledger of choice?

Crypto Explainer-in-Chief, Columbia Business School adjunct professor, and author of Re-Architecting Trust: the Curse of History and the Crypto Cure for Money, Markets and Platforms, Omid Malekan, says: take a pause. Don’t let cryptocrime deter you from seeing the value (and safety wins!) in decentralized finance.

Omid’s Thoughts

“Everyone’s heard the cliche that crypto is an enabler of illicit activity, and if all you do is read headlines like the one today that the Justice Department just recovered billions of dollars worth of stolen Bitcoin, then you might think that it’s true. But if you read past the headlines and look at the sophisticated tools that the government has developed to take advantage of unique features of crypto, like total transparency of every transaction, then you’ll see that increasingly.

It’s foolish to try to use Bitcoin for illicit activity because in many ways it’s easier for law enforcement to, quote unquote, ‘follow the money’ on the blockchain than it is through the traditional banking system. Project this forward a few years, assume that the government, with the help of private companies, will keep improving its ability to trace illicit activity through crypto, and it’s not unreasonable to assume that criminals will be more likely to use the existing banking system where trillions of dollars still get laundered every year, and the opacity makes it hard for the governments to stop.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More